• Explore /
  • Poster
  • / SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST).

SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST).

Abstract Poster

Authors

null

Brigitte C. Widemann

Center for Cancer Research, National Cancer Institute, Bethesda, MD

Brigitte C. Widemann , Christian Frederick Meyer , Gregory Michael Cote , Rashmi Chugh , Mohammed M. Milhem , Brian Andrew Van Tine , AeRang Kim , Brian Turpin , Eva Dombi , Nalini Jayaprakash , Scott H. Okuno , Lee J. Helman , Ndidi Onwudiwe , Seth M. Steinberg , Denise K. Reinke , Karen Cichowski , John Peter Perentesis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Clinical Trial Registration Number

NCT01661283

Citation

J Clin Oncol 34, 2016 (suppl; abstr 11053)

DOI

10.1200/JCO.2016.34.15_suppl.11053

Abstract #

11053

Poster Bd #

179

Abstract Disclosures

Similar Posters

First Author: Andrea P. Myers

First Author: E. Jonasch

First Author: Darren R. Feldman

First Author: Thomas Cosgriff